Ipsum Diagnostics LLC – Trademark Portfolio

Entity Type: 16

Ipsum Diagnostics LLC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include COV-19 IDX. The owner is based in Atlanta, GA.

Suite 125

8607 Roberts Drive

Atlanta, GA 30350

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Ipsum Diagnostics LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Ipsum Diagnostics LLC have?

Ipsum Diagnostics LLC has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does Ipsum Diagnostics LLC file in?

Ipsum Diagnostics LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are Ipsum Diagnostics LLC's most well-known trademarks?

Ipsum Diagnostics LLC's registered trademark portfolio includes well-known marks such as COV-19 IDX. These are among 1 currently registered trademark in the portfolio.

What is Ipsum Diagnostics LLC's trademark registration success rate?

Ipsum Diagnostics LLC has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.